Search results
31 paź 2014 · Bullous systemic lupus erythematosus (BSLE) is an uncommon blistering eruption that can occur in patients with systemic lupus erythematosus (SLE). Between 59 and 85 % of SLE patients will have skin manifestations of their disease, but less than 5 % will develop bullous disease [ 1 – 3 ].
8 lis 2023 · Bullous SLE is rare blistering disorder characterized by subepidermal blisters. We, hereby, present a case of bullous SLE in a 24-year-old female who responded well to systemic glucocorticoids, mycophenolate mofetil, and dapsone.
22 maj 2023 · Bullous systemic lupus erythematosus (BSLE) is a rare blistering eruption seen in patients with systemic lupus erythematosus (SLE) described mainly in case reports, series, and a few multicenter retrospective studies.
25 lut 2019 · Bullous systemic lupus erythematosus: a review and update to diagnosis and treatment. Am J Clin Dermatol . 2014; 15 ( 6 ):517-24. 10.1007/s40257-014-0098-0. [ PubMed ] [ CrossRef ] [ Google Scholar ]
Bullous systemic lupus erythematosus (BSLE) is a rare cutaneous complication of systemic lupus ery-thematosus (SLE). It is a heterogeneous disease that is caused by autoantibodies to the dermoepidermal junction, mainly type VII collagen.
In addition, rituximab was recently found to be efficacious in recalcitrant cases of BSLE that do not respond to dapsone and immunosuppressants. We review the topic of BSLE with emphasis on clinical, histologic, and immunopathologic features, as well as new methods of diagnosis and treatment.
11 maj 2022 · Anecdotal reports of successful use of belimumab for cutaneous lupus refractory to other medications, including intravenous immunoglobulin (IVIG) and rituximab, have been encouraging . In the retrospective study by Iaccarino et al ., 188 active SLE patients from 11 Italian cohorts were treated using belimumab [ 32 ].
